Hypertension

• CLINICAL_TRIALS trial_result · 2024-05-02
  Clinical Trial Update: Using Night-time Blood Pressure to Treat Hypertension [NA]

  A clinical trial conducted at the Chinese University of Hong Kong evaluating night-time blood pressure management as a treatment for hyperte…

• CLINICAL_TRIALS research · 2024-05-01
  Clinical Trial Update: Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients

  A clinical trial investigating how home blood pressure variability relates to arteriosclerosis and metabolic dysfunction in hypertensive pat…

• FDA approval · 2024-04-30
  FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)

  FDA approves a supplemental application for Jubilant Cadista's generic Losartan potassium and hydrochlorothiazide product.

• FDA label_change · 2024-04-30
  FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Alembic Pharmaceuticals Limited)

  The FDA approved a supplemental application for valsartan and hydrochlorothiazide by Alembic Pharmaceuticals Limited, resulting in updates t…

• FDA approval · 2024-04-30
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Accord Healthcare Inc.)

  The FDA approved a supplemental application for hydrochlorothiazide filed by Accord Healthcare Inc. under ANDA 202556. The document does not…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2024-04-30
  FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Zydus Lifesciences Limited)

  The FDA approved a supplemental application for a valsartan and hydrochlorothiazide generic product from Zydus Lifesciences Limited.

• FDA approval · 2024-04-30
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (ScieGen Pharmaceuticals Inc)

  The FDA approved a supplemental application for hydrochlorothiazide submitted by ScieGen Pharmaceuticals Inc., endorsing changes to the prod…

• CLINICAL_TRIALS trial_result · 2024-04-29
  Clinical Trial Update: Effect of Home-exercise Programs Versus Supervised Core Stability Exercises on Hypertensive Patient With Low Back Pain [NA]

  The study comparing home-exercise programs versus supervised core stability exercises in hypertensive patients with low back pain has comple…

• CLINICAL_TRIALS trial_result · 2024-04-29
  Clinical Trial Update: Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers [NA]

  This clinical trial evaluated strategies to prevent weight gain and control blood pressure during smoking cessation in hypertensive smokers.…

• CLINICAL_TRIALS trial_result · 2024-04-29
  Clinical Trial Update: Telemedicine Management of Hypertension [NA]

  This document reports the completion of a clinical trial evaluating telemedicine management for hypertension.

• CLINICAL_TRIALS research · 2024-04-26
  Clinical Trial Update: Genetics of Hypertension Associated Treatments (GenHAT)

  GenHAT is a genetics-focused clinical trial examining how genetic variation influences responses to hypertension treatments; the study statu…

• CLINICAL_TRIALS research · 2024-04-25
  Clinical Trial Update: The African-PREDICT Study

  The African-PREDICT study, sponsored by North-West University in South Africa, investigates cardiovascular diseases and hypertension with a …

• CLINICAL_TRIALS trial_result · 2024-04-23
  Clinical Trial Update: A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention [NA]

  A completed clinical trial evaluating a nurse-led intervention to extend the HIV treatment cascade and support cardiovascular disease preven…

• FDA approval · 2024-04-23
  FDA Approved: VERAPAMIL HYDROCHLORIDE — Original Application (FRESENIUS KABI USA, LLC)

  FDA approved the original application for Verapamil hydrochloride as a generic drug, manufactured by Fresenius Kabi USA, LLC. Verapamil hydr…

• FDA approval · 2024-04-17
  FDA Approved: NICARDIPINE HYDROCHLORIDE IN SODIUM CHLORIDE — Original Application (WG Critical Care, LLC)

  FDA approved the original ANDA for NICARDIPINE HYDROCHLORIDE IN SODIUM CHLORIDE, a generic intravenous formulation from WG Critical Care, LL…

• CLINICAL_TRIALS trial_result · 2024-04-17
  Clinical Trial Update: SPYRAL DYSTAL Renal Denervation Global Clinical Study [NA]

  Clinical trial update for SPYRAL DYSTAL Renal Denervation study conducted by Medtronic Vascular; trial status completed with results posted …

• CLINICAL_TRIALS trial_result · 2024-04-16
  Clinical Trial Update: Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. [Phase 4]

  Phase 4 trial investigating whether adding carvedilolCR to ACE inhibitors provides vascular benefits in patients with type 2 diabetes and hy…

• FDA approval · 2024-04-16
  FDA Approved: CARVEDILOL PHOSPHATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)

  FDA approved a supplemental application for carvedilol phosphate from Sun Pharmaceutical, confirming approval of this generic salt formulati…

• CLINICAL_TRIALS research · 2024-04-12
  Clinical Trial Update: Understanding the Exercise-Hypertension Paradox [NA]

  A completed clinical trial update examining the exercise-hypertension paradox, with results posted in 2024.

• FDA approval · 2024-04-11
  FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)

  FDA granted approval of a supplemental application for valsartan and hydrochlorothiazide by Mylan Pharmaceuticals, enabling its generic prod…

• CLINICAL_TRIALS research · 2024-04-09
  Clinical Trial Update: Supporting Self-Management of Healthy Behaviors in Chronic Kidney Disease [NA]

  This ClinicalTrials.gov update notes the study is completed and results have been posted for a University of Pennsylvania trial evaluating s…

• CLINICAL_TRIALS trial_result · 2024-04-05
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AD-209 [Phase 2]

  Phase 2 clinical trial assessing efficacy and safety of AD-209 for hypertension (essential hypertension) has completed.

• FDA approval · 2024-04-04
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)

  FDA approved a supplemental application for Hydrochlorothiazide from Aurobindo Pharma Limited (generic).

• FDA approval · 2024-04-02
  FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (GLENMARK PHARMACEUTICALS INC., USA)

  FDA approved a supplemental application for a generic fixed-dose combination of bisoprolol fumarate and hydrochlorothiazide for hypertension…

• FDA approval · 2024-04-02
  FDA Approved: FUROSEMIDE — Original Application (Devatis Inc.)

  FDA approved Devatis Inc.'s original application for a generic furosemide product, enabling its marketing in the United States.